In a patient with inflammatory triple-positive breast cancer who has a pCR to neoadjuvant chemotherapy, but has an incidentally found focus of intermediate-grade ER+/PR+/HER2- ILC in the mastectomy specimen, how would this impact your adjuvant radiation recommendations?
This finding would not have any impact on my recommendations, since her management needs to be guided by the inflammatory breast cancer. That means chest wall plus nodal irradiation tailored to the findings of axillary surgery. There are no data on whether we can decrease the dose in patients with a...
Join for free or sign in to see the full answer
Inflammatory breast cancer is an uncommon subtype with a poor prognosis and high frequency of both distant mets and local recurrence. Patients are not generally operable at presentation. NCCN guidelines call for initial systemic therapy with good responders proceeding to mastectomy followed by posto...
Join for free or sign in to see the full answer
I would treat it like a principle for inflammatory breast cancer, where I consider a scar boost even for pCR or boost any undissected GTV nodes.
Join for free or sign in to see the full answer